Audited Standalone Financial Results for the quarter and year ended 31st March 2025 along with Audit report
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 3.6 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indrayani Biotech Limited reported audited standalone results for the quarter and year ended 31 March 2025 with an unmodified auditor opinion from Venkatesh & Co. Revenue from operations for FY25 fell sharply to Rs 3,776.91 lakhs from Rs 6,232.34 lakhs in FY24, a decline of about 39%. Total income stood at Rs 4,128.51 lakhs versus Rs 6,594.22 lakhs. Profit before tax dropped to Rs 64.63 lakhs from Rs 300.91 lakhs, but profit after tax was broadly flat at Rs 144.63 lakhs (vs Rs 145.74 lakhs), supported by a Rs 80 lakh deferred tax credit. Basic EPS for the year was Rs 0.32 vs Rs 0.37. Finance costs surged 52% to Rs 732.10 lakhs, pressuring margins despite a higher operating margin on lower revenue. The board also noted the resignation of Company Secretary V Santhanakrishnan effective 13 June 2025; consolidated results were deferred to the next day.
Shareholders should note a sharp drop in top-line revenue alongside a steep rise in finance costs, though bottom-line profit held steady on a tax benefit. The auditor's clean (unmodified) opinion and stable equity base are positives, but the declining revenue trend and elevated borrowings warrant close monitoring.